3. Duplicative Therapy

Adjunctive administration of multiple GLP-1 agonists is not recommended due to increased risk for adverse events with no additional therapeutic benefit. Exenatide regular-release should be discontinued prior to initiating exenatide extended-release therapy. Patient profiles containing prescriptions for multiple GLP-1 agonists will be reviewed.